Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MUM-VTE: Prevention of Postpartum Venous Thromboembolism in Women at Intermediate Risk
NCT06845423Phase 4Recruiting
- Sponsor
- Centre Hospitalier Universitaire de Brest
- Start
- May 2025
- Primary completion
- May 2028
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of low molecular weight heparin calcium in venous thromboembolism (VTE) (2 arms), sponsored by Centre Hospitalier Universitaire de Brest. Primary endpoint: Symptomatic Venous Thromboembolism at 6 weeks. Started May 2025; status: recruiting.
02
Drugs
low molecular weight heparin calcium
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on NCT06845423.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06845423.